Atazanavir

Routes
Oral (PO)
Half-Life (t½)
PO: 12h
Formula
C38H52N6O7
Molecular Weight
704.86 g/mol
PubChem CID
148192
Aliases
Reyataz, ATV

Pharmacological Mechanism

HIV protease inhibitor — competitive inhibition of HIV-1 aspartyl protease blocks gag/gag-pol polyprotein cleavage and prevents production of mature virions. Almost always coadministered with a CYP3A4 booster (cobicistat or ritonavir) for adequate exposure. Distinctive among PIs for its inhibition of UGT1A1 — causes asymptomatic Gilbert-like unconjugated hyperbilirubinemia in most users (visible as scleral icterus at high exposure); not hepatotoxic, doesn't require discontinuation. Requires acid for absorption — clinically significant interaction with PPIs / H2 blockers / antacids. Otherwise generally well tolerated long-term. PK (Reyataz label, boosted 300/100 mg PO qd with RTV at SS): Cmax 6129 ng/mL, AUC(0-24) 57039 ng·h/mL, Tmax ~2.5 h, t½ 9-18 h boosted (7-8 h unboosted). Light meal ↑ AUC ~33% + Cmax ~40% (food taken with dose). CL/F ≈ 5.3 L/h, V/F ≈ 91 L.

Half-Life & Elimination Curve (PO: 12h)

100%50%25%12.5%0%0h0×t½12h1×t½24h2×t½36h3×t½48h4×t½60h5×t½0×t½ (0h): 100% remaining (~2.57 mg/L)1×t½ (12h): 50% remaining (~1.28 mg/L)2×t½ (24h): 25% remaining (~0.642 mg/L)3×t½ (36h): 12.5% remaining (~0.321 mg/L)4×t½ (48h): 6.3% remaining (~0.161 mg/L)5×t½ (60h): 3.1% remaining (~80.3 µg/L)
Plasma (PO)t½ Decay (12h)
  • 0×t½0h100% (2.57 mg/L)
  • 1×t½12h50% (1.28 mg/L)
  • 2×t½24h25% (0.642 mg/L)
  • 3×t½36h12.5% (0.321 mg/L)
  • 4×t½48h6.3% (0.161 mg/L)
  • 5×t½60h3.1% (80.3 µg/L)
Elimination t½12h (PO)
Rate Constant (ke)0.0578 h⁻¹
Time to Peak (Tmax)4.32h
Est. Peak (Cmax)2.57 mg/L
Clearance (CL)5.26 L/h
97% Washout (5×t½)60h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References